首页> 外文期刊>Bone marrow transplantation >Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.
【24h】

Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.

机译:在严重再生障碍性贫血的替代供体骨髓移植中,包含制备方案的非全身照射。

获取原文
获取原文并翻译 | 示例
       

摘要

Using non-total body irradiation (TBI) containing preparative regimens, 13 patients with severe aplastic anemia (SAA) were transplanted from an alternative donor in a single institute. In total, 12 donors were unrelated volunteers and one was an HLA one-locus mismatched sibling. Median time from diagnosis of SAA to bone marrow transplantation (BMT) was 10.1 months (range, 1.6-180.1). Nine patients had received immunosuppressive treatment with ATG before BMT, while four had not. Preparative regimens consisted of cyclophosphamide plus ATG in nine patients, cyclophosphamide plus fludarabine in two patients, and cyclophosphamide plus fludarabine plus ATG in two patients. All patients received non-T-cell depleted bone marrow from the donor. Cyclosporine plus methotrexate were given for GVHD prophylaxis. All patients engrafted on a median of day 21 (range, 15-27). Grade III-IV acute GVHD developed in three (23%) of 13 patients and extensive chronic GVHD in four (31%) of 12 evaluable patients. With a median follow-up duration of 1138 days (range, 118-1553), 10 patients are alive with durable engraftment showing 74.6% (95% confidence interval, 49.5-99.7%) of survival rate. Cause of the deaths was CNS bleeding in one and chronic GVHD in two. In conclusion, non-TBI containing preparative regimen could ensure durable engraftment in alternative donor BMT for SAA and showed promising results.
机译:使用包含制备方案的非全身照射(TBI),从一家机构的另一位供体中移植了13例严重再生障碍性贫血(SAA)患者。总共有12位捐赠者是无关的志愿者,其中一位是HLA单基因位错配的同胞。从诊断出SAA到骨髓移植(BMT)的中位时间为10.1个月(范围1.6-180.1)。 BMT前有9名患者接受了ATG的免疫抑制治疗,而4名则没有。制备方案由9例患者的环磷酰胺加ATG,2例患者的环磷酰胺加氟达拉滨和2例患者的环磷酰胺加氟达拉滨加ATG组成。所有患者均接受来自供体的非T细胞耗竭的骨髓。给予环孢霉素加甲氨蝶呤预防GVHD。所有患者在第21天(范围15-27)中位移植。在13例患者中有3例(23%)发生了III-IV级急性GVHD,在12例可评估患者中有4例(31%)出现了广泛的慢性GVHD。中位随访时间为1138天(范围:118-1553),有10例患者存活并接受了持久移植,存活率为74.6%(95%置信区间为49.5-99.7%)。死亡的原因之一是中枢神经系统出血,而另一例是慢性GVHD。总之,不含TBI的制备方案可确保SAA替代供体BMT的持久植入,并显示出可喜的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号